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Abstract
Background: Neuroinflammation plays a prominent role in the progression of Alzheimer's disease
and may be responsible for degeneration in vulnerable regions such as the hippocampus.
Neuroinflammation is associated with elevated levels of extracellular glutamate and potentially an
enhanced stimulation of glutamate N-methyl-D-aspartate receptors. This suggests that neurons
that express these glutamate receptors might be at increased risk of degeneration in the presence
of chronic neuroinflammation.
Methods: We have characterized a novel model of chronic brain inflammation using a slow
infusion of lipopolysaccharide into the 4th ventricle of rats. This model reproduces many of the
behavioral, electrophysiological, neurochemical and neuropathological changes associated with
Alzheimer's disease.
Results: The current study demonstrated that chronic neuroinflammation is associated with the
loss of N-methyl-D-aspartate receptors, as determined both qualitatively by
immunohistochemistry and quantitatively by in vitro binding studies using [3H]MK-801, within the
hippocampus and entorhinal cortex.
Conclusion: The gradual loss of function of this critical receptor within the temporal lobe region
may contribute to some of the cognitive deficits observed in patients with Alzheimer's disease.
Background
Neuroinflammation plays a prominent role in the pro-
gression of Alzheimer's disease [AD, [1,2]]. Brain regions,
particularly those involved in learning and memory,
which demonstrate the greatest degree of microglia cell
activation early in the disease ultimately show the highest
rate of atrophy and pathology [3]. Neurons within the
entorhinal cortex (EC) and hippocampus degenerate in
AD [4,5] and are particularly vulnerable to the conse-
quences of chronic neuroinflammation and aging [6-9].
Although the mechanism underlying the degeneration of
these cells is unknown, excitotoxicity via the stimulation
of glutamate receptors may play an important role [10-
15]. Glutamate N-methyl-D-aspartate (NMDA) receptors
are highly concentrated in the hippocampus and EC and
their activation has a dual role in normal neuroplasticity
as well as neurodegeneration [12,16,17]. Impaired
NMDA receptor function may therefore contribute to the
cognitive deficit observed in AD [18,19]. The number of
NMDA receptors within the hippocampus, EC and basal
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forebrain substantia innominata declined following an
acute neuroinflammatory challenge produced by an injec-
tion of lipopolysaccharide (LPS) into the cisterna magna
[20]. Therefore, neurons that express NMDA receptors
within these brain regions might be at increased risk in the
presence of chronic neuroinflammation similar to that
present in the brains of AD patients [1,3]. Brain inflam-
mation leads to increased extracellular levels of glutamate
[21] that may induce increased calcium entry through the
NMDA receptors and the degeneration or dysfunction of
NMDA receptive neurons [22]. Activated glia may also
potentiate NMDA-mediated toxicity via the production
and release of nitric oxide [23] or interleukin-1β [24], sug-
gesting that neuroinflammation may exacerbate excito-
toxicity in neurons.
We have developed a model of chronic brain inflamma-
tion using a slow LPS infusion into the 4th ventricle of rats
that reproduces many of the behavioral, electrophysiolog-
ical, neurochemical and neuropathological changes asso-
ciated with AD [14,15], including the presence of
activated microglia within the hippocampus and EC,
impaired long term potentiation in the dentate gyrus,
impaired learning and memory, and a significant loss of
CA3 hippocampal pyramidal cells and entorhinal pyram-
idal neurons in layers II & III [6-9,25-27]. Similarly, the
long term infusion of LPS into the basal forebrain was
associated with the selective degeneration of cholinergic
basal forebrain neurons [13,14]. A critical role for stimu-
lation of the NMDA receptors is supported by the finding
that the neurodegenerative consequences of chronic neu-
roinflammation upon basal forebrain cholinergic neu-
rons can be reversed by treatment with the NMDA
receptor antagonist memantine [13,14]. The current study
demonstrates that chronic neuroinflammation is associ-
ated with the loss of NMDA receptors within the hippoc-
ampus and EC. Because NMDA receptors contain the
obligatory NR1 subunit [28], receptor localization was
determined using a monoclonal antibody that recognizes
all variants of the NR1 subunit. A quantitative verification
of the loss of these receptor sites is also shown using an in
vitro binding assay with [3H]-MK-801.
Methods
Subjects
Twenty-two young (3 months old) male F-344 rats (Har-
lan Sprague-Dawley, Indianapolis, IN) were singly
housed in Plexiglas cages with free access to food and
water. The rats were maintained on a 12/12-h light-dark
cycle in a temperature-controlled room (22°C) with lights
off at 0800. All rats were given health checks, handled
upon arrival and allowed at least one week to adapt to
their new environment prior to surgery.
Materials
LPS (E. coli, serotype 055:B5) was obtained from Sigma
Chem. (St. Louis, MO). [3H]MK801 was obtained from
New England Nuclear, Boston, MA.
Surgical procedures
Standard procedures were used for the surgery [6,9]. Each
rat was anesthetized with isoflurane gas and placed in a
stereotaxic instrument with the incisor bar set 3.0 mm
below the ear bars. The scalp was incised and retracted
and a hole was made at the appropriate location in the
skull with a dental drill. A chronic indwelling cannula was
inserted into the 4th ventricle. Coordinates for the 4th ven-
tricle infusions were as follows: 2.5 mm posterior to
Lambda, on the mid-line, and 7.0 mm ventral to the dura.
An osmotic minipump (Alzet, Palo Alto, CA, model 2004,
to deliver 250 ηL/h) was attached via a catheter to a
chronic indwelling cannula that had been positioned ster-
eotaxically so that the tip extended to the coordinates
given above. Each minipump was prepared to inject either
the vehicle artificial cerebrospinal fluid (aCSF) or 250 ηg
LPS/h (prepared in aCSF). The composition of the aCSF
(in mmol/L) was 140 NaCl; 3.0 KCl; 2.5 CaCl2; 1.2
Na2HPO4, pH 7.4. The following post-operative care was
provided to all rats: betadine was applied to the exposed
skull and scalp prior to closure to limit local infection and
5 ml of sterile isotonic saline were injected subcutane-
ously to prevent dehydration during recovery. The rats
were closely monitored during recovery and kept in an
incubator (Ohio Medical Products, Madison, WI) at tem-
peratures ranging from 30–33°C. Body weights were
determined daily and general behavior was monitored for
seizures.
Immunohistochemistry
Twenty-nine days after surgery rats from each group were
anesthetized and were either transcardially perfused with
cold saline containing 1 U/ml heparin, followed by 4%
paraformaldehyde in 0.1 M sodium phosphate buffer, pH
7.4, or sacrificed by decapitation, the brains frozen (-
70°C) and used for the fluorescence labeling studies. The
perfused brains were post-fixed one hour in the same fix-
ative and then stored (4°C) in phosphate buffered saline,
pH 7.4. Free-floating, serial coronal sections (40 µm) were
taken by vibratome from perfused tissues for staining with
standard avidin/biotin peroxidase methods. The frozen
brains were arranged into a block of gelatin as a group of
three brains representing rats from both groups in order to
reduce variability in the immunostaining between slides.
The blocks were then sectioned (20 µm) using a cryostat
and prepared for fluorescence labeling. The monoclonal
antibody OX-6 (final dilution 1:400, Chemicon, San
Diego, USA) was used to visualize activated microglia cells
[6]. This antibody is directed against Class II major histo-
compatibility complex (MHC II) antigen. Since NMDAJournal of Neuroinflammation 2004, 1:12 http://www.jneuroinflammation.com/content/1/1/12
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receptors contain the obligatory NR1 subunit [28], in
order to label all NMDA receptors with equal probability,
we used a monoclonal antibody anti-NR1 subunit spe-
cific, NMDAR1 (Chemicon, final dilution 1:250). After
quenching endogenous peroxidase activity and blocking
nonspecific binding, the sections were incubated (4°C)
either overnight (for OX-6) or 3 days (for NMDAR1) with
primary antibodies directed against the specific epitopes
(MCH II and R1, respectively). Thereafter, the sections
were incubated for 2 h (22°C) with the secondary mono-
clonal antibody, rat adsorbed biotinylated horse anti-
mouse immunoglobulin G (final dilution 1:200, Vector,
Burlingame, USA), Sections were than incubated for 1 h
(22°C) with avidin-biotinylated horseradish peroxydase
(Vectastain, Elite ABC kit, Vector). After washing again in
PBS, the sections were incubated with 0.05% 3,3'-diami-
nobenzidine tetrahydrochloride (Vector) as chromogen.
The reaction was stopped by washing the sections with
buffer. No staining was detected in the absence of the pri-
mary or secondary antibodies. Sections were mounted on
gelatin-chrome-alum-coated glass slides, air-dried and
coverslipped with Cytoseal (Allan Scientific, Kalamazoo,
MI) mounting medium. The location of immunohisto-
chemically-defined cells was examined by light micros-
copy. Immunofluorescence was visualized with
fluorescent substrates (FITC, Fluorescein, Perkin-Elmer,
Boston, MA) and all nuclei were counterstained with
ToPro3 (1:1,000 in TBS, Molecular Probes). A Z-section
image series were acquired using a confocal microscope
(Carl Zeiss, model 510NLO-META, Thornwood, NY) with
a 25 × water immersion objective. Pinhole size and con-
trast values were kept constant for each area on a slide. No
staining was detected in the absence of the primary or sec-
ondary antibodies.
[3H]-MK-801 Receptor Binding Assay
The entire left hippocampus from the brain of four rats
infused with aCSF and four infused with LPS for four
weeks was isolated and stored (-70°C) until assayed for
NMDA receptors using [3H]MK-801 according to a modi-
fied method previously described [7]. Crude membrane
fractions were prepared by initial homogenization in 20
volumes of 0.32 M sucrose containing 1.0 mM EGTA and
centrifuged at 1000 × g for 10 min at 4°C. The resulting
supernatant was centrifuged at 40,000 × g for 40 min at
4°C. The resulting pellet was resuspended in 20 volumes
of 1.0 mM EGTA and centrifuged (40,000 × g, 40 min,
4°C). The pellet was resuspended in 50 mM Tris-acetate
buffer (pH 7.4) and centrifuged (47,900 × g, 10 min,
4°C). This final sequence was repeated three times to
remove any endogenous components of the tissue that
might interfere with binding. The tissues were stored fro-
zen overnight and then centrifuged again (47,900 × g, 10
min, 4°C). The final pellet was resuspended in 15 vol-
umes (to achieve approx. 0.4 mg/ml protein) of 50 mM
Tris acetate buffer. The homogenate was used immedi-
ately for binding studies. Due to the small size of the sam-
ples and the desire to avoid pooling tissues only single-
point determinations were made. The assays were con-
ducted in an incubation volume of 500 µl containing
[3H]MK-801 (1.0 ηM) and 100–150 µg of membrane pro-
tein at 25°C for 60 min in the presence of 100 µM glycine
and 50 µM spermidine. Non-specific binding was defined
by the addition of 10 µM MK-801. Incubation was termi-
nated by dilution with 4 ml of ice-cold 50 mM Tris-acetate
buffer, pH 7.4, followed immediately by rapid filtration
through Whatman GF/B glass fiber filters on a cell har-
vester (Brandel, model PHD 2000, Gaithersburg, MD).
The filters were rinsed three times with 4 ml of buffer. All
filters were presoaked in 0.3% polyethylenimine (pH 7.0)
for at least 2 h at 25°C. The filter-bound radioactivity was
determined by liquid scintillation spectrometry. Mem-
brane protein levels were determined [29] with bovine
serum albumin as standard. The results were analyzed by
Student's t-test. (SigmaStat software, Jandel Scientific, San
Rafael, CA).
Results
Overall, chronic infusion of LPS was well tolerated by all
rats. Initially after surgery, all LPS-treated rats lost only a
few grams of weight. Within a few days, however, most
rats had regained weight and continued to gain weight
normally for the duration of the study.
Immunohistochemistry
LPS infused rats had numerous, highly activated microglia
cells (OX-6 positive) distributed throughout the hippoc-
ampus and EC (see Figure 1). Rats infused with aCSF
showed only a few mildly activated microglia scattered
throughout the brain (Figure 1A), similar to our previous
reports [6,9,10]. Activated microglia were widely scattered
throughout the hippocampus (Figure 1B) and were char-
acterized by a contraction of their highly ramified proc-
esses that appeared bushy in morphology (Figure 1C,1D).
Rats infused with aCSF showed numerous NMDAR1
immunoreactive large neurons throughout the hippocam-
pus and EC that had intense dark staining within the cyto-
plasm of the cell bodies that extended into the dendrites.
Chronic infusion of LPS for four weeks reduced the
number of NMDAR1-immunoreactive cells within the
hilar region of the dentate gyrus as well as in area CA3, as
compared to the staining in these hippocampal regions of
rats infused with aCSF (see Figure 2). Chronic infusion of
LPS had a lesser effect upon NMDAR1 immunoreactivity
within cells in the EC (Figure 3).
[3H]-MK-801 Receptor Binding Assay
Rats chronically infused with LPS had significantly (t =
10.8, df = 6, p < 0.001) fewer [3H]MK-801 binding sites inJournal of Neuroinflammation 2004, 1:12 http://www.jneuroinflammation.com/content/1/1/12
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the hippocampus compared to the aCSF infused animals
(See Figure 4).
Discussion
Chronic neuroinflammation in young rats produced by
infusion of LPS into the 4th ventricle for 28 days was asso-
ciated with an increased number of highly activated
microglia cells throughout the temporal lobe and greatly
decreased immunolabelling of NMDAR1 receptors within
the pyramidal layer of the CA3 and hilar regions of the
dendate gyrus and to a somewhat less degree within the
EC. The loss of immunostaining may reflect either dimin-
ished receptor protein concentration or an inflammation-
induced conformational change in the protein structure
such that the antibody no longer recognized its antigenic
binding site. We have previously shown using electron
Confocal microscope images of activated microglial cells MHC II (green OX-6 positive) in the Dentate Gyrus Figure 1
Confocal microscope images of activated microglial cells MHC II (green OX-6 positive) in the Dentate Gyrus. Rats infused with 
aCSF (A) had only a few activated microglia scattered throughout the brain. Chronic infusion of LPS into the 4th ventricle pro-
duced high activated microglia distributed throughout the hippocampus (B). Higher magnifications of an activated microglia (C, 
D) show the characteristic contracted and ramified processes with bushy morphology. Cell nuclei are stained red (ToPro3). 
Scale bars: (A-B) 100 µm; (C) 25 µm; (D) 2.5 µm.
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microscopy that chronic neuroinflammation in the hip-
pocampus is associated with numerous changes in the
intracellular components involved in the protein synthe-
sis; in contrast, no significant changes were associated
with the mitochondria or lysosomes [25]. The decline in
immunoreactive receptor sites was paralleled by a decline
in the number of [3H]MK-801 binding sites within the
hippocampus, which is consistent with a previous report
on the effects of acute exposure to LPS upon NMDA recep-
tor density within this brain region [20]. Taken together,
these findings are consistent with the hypothesis that
selected vulnerable cells degenerated as a consequence of
the chronic neuroinflammatory processes. We have previ-
ously shown that neurons in the EC degenerated in a
model of chronic neuroinflammation similar to that used
in the present study [6,8,9]. We speculate that the loss of
entorhinal afferents might underlie a component of the
decline in NMDA R1 immunoreactivity within the hip-
pocampus [30] given that the EC provides the main gluta-
matergic afferents to the hippocampus via the perforant
pathway and this is usually the first region to undergo
degenerative changes in AD [5,31]. Because so little is
known regarding the consequences of long term neuroin-
flammation produced in this model, it is impossible to be
certain whether the loss of NMDA glutamate receptors
that we report is selective for this brain region or this par-
ticular receptor. We have previously only documented the
loss of pyramidal neurons using this model [6] although
we are currently pursuing this question.
In the current model of chronic brain inflammation we
have hypothesized the following sequence of events
Confocal microscopic images of NMDAR1 receptors within the hippocampus Figure 2
Confocal microscopic images of NMDAR1 receptors within the hippocampus. In rats infused with aCSF (A, B, C), fluorescence 
labeling showed large NMDAR1-positive neurons (red) in dentate gyrus (A), hilar region (B) and CA3 area (C). All nuclei are 
stained green (Sytox). Scale bars: (A) 100 µm; (B, C) 25 µm. Immunohistochemistry of NMDAR1-positive neurons revealed 
dark staining in the cytoplasm that extended along the dendrites in cells within the dentate gyrus (G), hilar region (H), and CA3 
(I). Scale bars: (G) 100 µm; (H, I) 25 µm. Confocal microscopic images showed reduced NMDAR1 staining within the hippoc-
ampus of LPS infused rats: dentate gyrus (D), hilar region (E) and CA3 area (F). Scale bars: (D, E, F) 25 µm. Immunohistochem-
istry of NMDAR1-positive neurons revealed fewer cells expressing NMDAR1 receptors with a lower degree of 
immunoreactivity throughout the dentate gyrus (J), hilar region (K) and CA3 (L). Scale bars: (J) 100 µm, (K, L) 25 µm.Journal of Neuroinflammation 2004, 1:12 http://www.jneuroinflammation.com/content/1/1/12
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leading to the degeneration of NMDA-expressing neurons
[14,15]. The infusion of LPS leads to the release of
inflammatory cytokines by activated astrocytes and
microglia [32]; these cytokines stimulate the production
of other inflammatory mediators such as prostaglandins
[33]; prostaglandins would induce the release of gluta-
mate from astrocytes [21,36] leading to increased levels of
extracellular glutamate and the stimulation of glutamate
receptors, the depolarization-dependent unblocking of
NMDA receptors by Mg2+, and the entry of toxic amounts
of Ca2+ into neurons and the subsequent generation of
toxic levels of nitric oxide and initiate a cascade of reactive
oxygen intermediates [34,35]. Prostaglandins and various
cytokines may also indirectly elevate the extracellular con-
centration of glutamate by inhibiting its reuptake by
astrocytes [37,38]; in addition, blockade of the uptake of
glutamate by astrocytes results in significant neurodegen-
eration [37,38]. We have hypothesized that a similar cas-
cade of biochemical events, possibly initiated by the loss
of forebrain norepinephrine [39], may occur associated
with normal aging [14,15,26]. Consistent with this
hypothesis and the results of the current study is a recent
report that chronic administration of an anti-inflamma-
tory drug could attenuate the age-related loss of hippoc-
ampal NMDAR1 receptors [40].
Conclusions
Taken together, our hypothesis and the results of our cur-
rent study suggest that neurons expressing NMDA recep-
tors would be vulnerable to degeneration in the presence
Immunostaining for activated microglia in the entorhinal cortex Figure 3
Immunostaining for activated microglia in the entorhinal cortex. Highly activated microglial cells (B) that are typical of LPS 
infused rats were completely absent in the brains of rats infused with aCSF (A). NMDAR1-immunoreactive cells within the 
entorhinal cortex of rats infused with aCSF (C) were characterized by darkly stained cell bodies and dendritic arbors. Rats 
infused with LPS (D) showed reduce level of immunoreactivity. Scale bars: (A, B) 100 µm; (C, D) 25 µm.
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of chronic neuroinflammation. Due to the widespread
presence of inflammation in vulnerable brain regions, a
similar series of biochemical processes might contribute
to the cognitive deficits observed in patients with AD [1-
3] or associated with normal aging [14].
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